A: K-11777 is a cysteine protease inhibitor that acts as a broad-spectrum antiviral by targeting cathepsin-mediated cell entry. It was observed to inhibit SARS-CoV virus entry in the sub-nanomolar range, suggesting a potential inhibitory effect on COVID-19 protease. Its dock score was 7.7.